Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

Patrick Terheyden; Maja Ann Hofmann; M. Weininger; Eva B. Bröcker; Jürgen C. Becker

doi:10.1007/s00432-007-0251-8

Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

Patrick Terheyden^*, Maja Ann Hofmann, M. Weininger, Eva B. Bröcker, Jürgen C. Becker

^*Corresponding author for this work

Clinic of Dermatology, Allergology and Venerology

20 Citations (Scopus)

Abstract

Purpose: The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated. Methods: We tested this notion in three patients with advanced and therapy-refractory melanoma. Results: Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis. Conclusion: Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.

Original language	English
Journal	Journal of Cancer Research and Clinical Oncology
Volume	133
Issue number	11
Pages (from-to)	897-901
Number of pages	5
ISSN	0171-5216
DOIs	https://doi.org/10.1007/s00432-007-0251-8
Publication status	Published - 11.2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00432-007-0251-8

Cite this

@article{3ae4225d2bbf4b609aef08949f376c23,

title = "Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma",

abstract = "Purpose: The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated. Methods: We tested this notion in three patients with advanced and therapy-refractory melanoma. Results: Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis. Conclusion: Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.",

author = "Patrick Terheyden and Hofmann, \{Maja Ann\} and M. Weininger and Br{\"o}cker, \{Eva B.\} and Becker, \{J{\"u}rgen C.\}",

year = "2007",

month = nov,

doi = "10.1007/s00432-007-0251-8",

language = "English",

volume = "133",

pages = "897--901",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "11",

}

TY - JOUR

T1 - Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

AU - Terheyden, Patrick

AU - Hofmann, Maja Ann

AU - Weininger, M.

AU - Bröcker, Eva B.

AU - Becker, Jürgen C.

PY - 2007/11

Y1 - 2007/11

N2 - Purpose: The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated. Methods: We tested this notion in three patients with advanced and therapy-refractory melanoma. Results: Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis. Conclusion: Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.

AB - Purpose: The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated. Methods: We tested this notion in three patients with advanced and therapy-refractory melanoma. Results: Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis. Conclusion: Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.

UR - https://www.scopus.com/pages/publications/36849048282

U2 - 10.1007/s00432-007-0251-8

DO - 10.1007/s00432-007-0251-8

M3 - Journal articles

C2 - 17583821

AN - SCOPUS:36849048282

SN - 0171-5216

VL - 133

SP - 897

EP - 901

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 11

ER -

Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this